April 2026 psychedelic bill round-up tracks US state and federal proposals on psilocybin, ibogaine, and broader reform, highlighting where legislation is advancing or stalling

US psychedelic policy activity in April 2026 centers on a cross-state legislative round-up covering bills that would expand access, fund research, create regulated therapeutic pathways, or change criminal penalties. The focus falls on how reform is moving unevenly across statehouses and at the federal level. Psilocybin and ibogaine appear as key policy anchors, with proposals tied to supervised treatment models, pilot programs, veterans' care, and research support. The round-up format emphasizes bill status, jurisdiction-by-jurisdiction developments, and practical differences between decriminalization, medical access, and licensed service systems. Broader significance lies in how psychedelic reform is becoming a conventional legislative category rather than a fringe issue. Tracking which measures advance, stall, or narrow in scope helps show where political momentum, institutional support, and implementation challenges are shaping the next phase of US policy change.